

BIBLIOGRAPHY

- Akaza, M. *et al.* (2018) 'Nerve conduction study of the association between glyceimic variability and diabetes neuropathy', *Diabetology and Metabolic Syndrome*. BioMed Central Ltd., 10(1), p. 69. doi: 10.1186/s13098-018-0371-0.
- Al-Mahroos, F. and Al-Roomi, K. (2007) 'Diabetic neuropathy, foot ulceration, peripheral vascular disease and potential risk factors among patients with diabetes in bahrain: a nationwide primary care diabetes clinic-based study', *Annals of Saudi Medicine*. King Faisal Specialist Hospital and Research Centre, 27(1), pp. 25–31. doi: 10.5144/0256-4947.2007.25.
- American Diabetes Association (2021) 'Standards of Medical Care in Diabetes-2021', *Diabetes Care*. American Diabetes Association, 44(Supplement 1). doi: 10.2337/dc21-S002.
- Boulton, A. J. M. *et al.* (2013) 'Whither pathogenetic treatments for diabetic polyneuropathy?', *Diabetes/Metabolism Research and Reviews*. John Wiley & Sons, Ltd, 29(5), pp. 327–333. doi: 10.1002/dmrr.2397.
- Cersosimo, E. *et al.* (2015) 'Pathogenesis of Type 2 Diabetes Mellitus ncbi'. MDText.com, Inc. Available at: <http://www.ncbi.nlm.nih.gov/books/NBK279115/> (Accessed: 3 January 2021).
- Colditz, G. A. *et al.* (1995) 'Weight gain as a risk factor for clinical diabetes mellitus in women', *Annals of Internal Medicine*. American College of Physicians, 122(7), pp. 481–486. doi: 10.7326/0003-4819-122-7-199504010-00001.
- Dahlan, M. S. (2010) *Besar Sample dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan*. Third Edit, Salemba Medika. Third Edit. Edited by A. Suslia. Jakarta: Salemba Medika.
- Diabetes Prevention Program Research Group (2002) 'Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin', *New England Journal of Medicine*. N Engl J Med, 346(6), pp. 393–403. doi: 10.1056/NEJMoa012512.
- Edelman, S. *et al.* (2006) 'A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes', *Diabetes Care*. American Diabetes Association, 29(10), pp. 2189–2195. doi: 10.2337/dc06-0042.
- Edwards, J. L. *et al.* (2008) 'Diabetic neuropathy: Mechanisms to management', *Pharmacology and Therapeutics*. Pergamon, pp. 1–34. doi: 10.1016/j.pharmthera.2008.05.005.

- England, J. D. *et al.* (2005) 'Distal symmetric polyneuropathy: A definition for clinical research: Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation', *Neurology*. Lippincott Williams and Wilkins, 64(2), pp. 199–207. doi: 10.1212/01.WNL.0000149522.32823.EA.
- Gonzalez-Clemente, J. M. *et al.* (2005) 'Diabetic neuropathy is associated with activation of the TNF-alpha system in subjects with type 1 diabetes mellitus', *Clinical Endocrinology*. John Wiley & Sons, Ltd, 63(5), pp. 525–529. doi: 10.1111/j.1365-2265.2005.02376.x.
- Goyal, R. and Jialal, I. (2020) *Diabetes Mellitus Type 2*, StatPearls Publishing LLC. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK513253/> (Accessed: 3 January 2021).
- Groener, J. B. *et al.* (2020) 'Understanding diabetic neuropathy—from subclinical nerve lesions to severe nerve fiber deficits: A cross-sectional study in patients with type 2 diabetes and healthy control subjects', *Diabetes*. American Diabetes Association Inc., 69(3), pp. 436–447. doi: 10.2337/db19-0197.
- Hamid, W. S. *et al.* (2021) 'Nerve conduction and its correlations with duration of diabetes mellitus and glycosylated haemoglobin in type 2 diabetes mellitus (T2DM)', *Journal of Endocrinology, Metabolism and Diabetes of South Africa*. Taylor & Francis, pp. 1–6. doi: 10.1080/16089677.2021.1877444.
- Hosny, S. S. *et al.* (2019) 'Relation between plasma Apelin level and peripheral neuropathy in Type 2 diabetic patients', *Diabetes and Metabolic Syndrome: Clinical Research and Reviews*. Elsevier Ltd, 13(1), pp. 626–629. doi: 10.1016/j.dsx.2018.11.027.
- Huang, C.-C. *et al.* (2005) 'Effect of Glycemic Control on Electrophysiologic Changes of Diabetic Neuropathy in Type 2 Diabetic Patients', *The Kaohsiung Journal of Medical Sciences*. Elsevier (Singapore) Pte Ltd, 21(1), pp. 15–21. doi: 10.1016/S1607-551X(09)70271-2.
- Ibrahim, O. K. (2017) *Nerve Conduction Studies in Type-II Diabetic Patients Under supervision of*. University of Basrah. Available at: <https://www.researchgate.net/publication/328175689>.
- Institute for Health Metrics and Evaluation (2017) *GBD Compare | IHME Viz Hub*, University of Washington. Available at: <https://vizhub.healthdata.org/gbd-compare/> (Accessed: 12 March 2020).
- Islam, M. R. *et al.* (2017) 'Electrophysiological Patterns of Diabetic Polyneuropathy: Experience from a Tertiary Care Hospital of Bangladesh', *BIRDEM Medical*

- Journal. Bangladesh Journals Online (JOL)*, 7(2), pp. 114–120. doi: 10.3329/birdem.v7i2.32448.
- Jaiswal, M. *et al.* (2013) ‘Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for diabetes in youth follow-up cohort: A pilot study’, *Diabetes Care*. American Diabetes Association, 36(12), pp. 3903–3908. doi: 10.2337/dc13-1213.
- Jeong, T. S. *et al.* (2003) ‘Relations of Glycosylated Hemoglobin and Parameters of Nerve Conduction Study in Diabetic Peripheral Polyneuropathy.’, *Journal of the Korean Academy of Rehabilitation Medicine*. Korean Academy of Rehabilitation Medicine, 27(1), pp. 80–84. Available at: <https://www.e-arm.org/journal/view.php?year=2003&vol=27&no=1&spage=80> (Accessed: 30 March 2021).
- Kamel, S. R. *et al.* (2015) ‘Clinical diagnosis of distal diabetic polyneuropathy using neurological examination scores: correlation with nerve conduction studies’, *Egyptian Rheumatology and Rehabilitation*. Springer Science and Business Media LLC, 42(3), p. 128. doi: 10.4103/1110-161x.163945.
- Kawamura, N. *et al.* (2008) ‘Inflammatory mediators in diabetic and non-diabetic lumbosacral radiculoplexus neuropathy’, *Acta Neuropathologica*, 115(2), pp. 231–239. doi: 10.1007/s00401-007-0326-2.
- Kiani, J. *et al.* (2013) ‘The Prevalence and Associated Risk Factors of Peripheral Diabetic Neuropathy in Hamedan, Iran’, *Archives of Iranian Medicine*. Hamedan, 16(1), pp. 17–19. Available at: <http://www.ams.ac.ir/AIM/NEWPUB/13/16/1/006.pdf> (Accessed: 4 January 2021).
- Lai, Y.-R. *et al.* (2019) ‘HbA1C Variability Is Strongly Associated With the Severity of Peripheral Neuropathy in Patients With Type 2 Diabetes’, *Frontiers in Neuroscience*. Frontiers Media S.A., 13(FEB), p. 90. doi: 10.3389/fnins.2019.00090.
- Lee, W. J. *et al.* (2016) ‘Correlation between the severity of diabetic peripheral polyneuropathy and glycosylated hemoglobin levels: A quantitative study’, *Annals of Rehabilitation Medicine*. Korean Academy of Rehabilitation Medicine, 40(2), pp. 263–270. doi: 10.5535/arm.2016.40.2.263.
- Majumder, A., Chatterjee, S. and Maji, D. (2013) *Peripheral neuropathy in diabetes - PubMed, Journal of Indian Medical Association*. Available at: <https://pubmed.ncbi.nlm.nih.gov/24761495/> (Accessed: 23 December 2020).
- Maruthur, N. M. *et al.* (2016) ‘Diabetes medications as monotherapy or metformin-based

- combination therapy for type 2 diabetes: A systematic review and meta-analysis', *Annals of Internal Medicine*. American College of Physicians, pp. 740–751. doi: 10.7326/M15-2650.
- Massey, C. N. *et al.* (2019) 'Well-being interventions for individuals with diabetes: A systematic review', *Diabetes Research and Clinical Practice*. Elsevier Ireland Ltd, pp. 118–133. doi: 10.1016/j.diabres.2018.11.014.
- Mayeda, L. *et al.* (2020) 'Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease', *BMJ Open Diabetes Research and Care*. BMJ Publishing Group, 8(1), p. 991. doi: 10.1136/bmjdr-2019-000991.
- Meijer, J. W. G. *et al.* (2003) 'Clinical diagnosis of diabetic polyneuropathy with the diabetic neuropathy symptom and diabetic neuropathy examination scores', *Diabetes Care*. American Diabetes Association, 26(3), pp. 697–701. doi: 10.2337/diacare.26.3.697.
- National Institute of Health (1998) *Clinical Guideline on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults*. NIH Publication.
- Nurlaela, S., Kurniawan, S. N. and Husna, M. (2019) 'ELECTRONEUROMYOGRAPHY EXAMINATION OF DIABETIC POLYNEUROPATHY PATIENTS', *MNJ (Malang Neurology Journal)*, 5(1), pp. 1–4. doi: 10.21776/ub.mnj.2019.005.01.1.
- Obrosova, I. G. *et al.* (2007) 'Role of nitrosative stress in early neuropathy and vascular dysfunction in streptozotocin-diabetic rats', *American Journal of Physiology - Endocrinology and Metabolism*. American Physiological Society, 293(6), pp. 1645–1655. doi: 10.1152/ajpendo.00479.2007.
- Paschou, S. A. *et al.* (2018) 'On type 1 diabetes mellitus pathogenesis', *Endocrine Connections*. BioScientifica Ltd., pp. R38–R46. doi: 10.1530/EC-17-0347.
- Pop-Busui, R. *et al.* (2017) 'Diabetic Neuropathy: A Position Statement by the American Diabetes Association', *Diabetes Care*. American Diabetes Association, 40(1), pp. 136–154. doi: 10.2337/DC16-2042.
- Preston, D. C. and Shapiro, B. E. (2013) *Electromyography and Neuromuscular Disorders*. 3rd Editio. Elsevier Inc. doi: 10.1002/mus/23894.
- Sari, D. T., Widasmara, D. and Kurniawan, S. N. (2018) 'Interpretation of Nerve Conduction Study in Polyneuropathy with Multibacillary Leprosy Type 2 Reaction', *MNJ (Malang Neurol Journal)*, 04(02), pp. 86–95. doi: 10.21776/ub.mnj.2018.004.02.7.

- Seferovic, J. P. *et al.* (2018) 'Retinopathy, neuropathy, and subsequent cardiovascular events in patients with type 2 diabetes and acute coronary syndrome in the ELIXA: The importance of disease duration', *Journal of Diabetes Research*. Hindawi Limited, 2018. doi: 10.1155/2018/1631263.
- Selvarajah, D. *et al.* (2006) 'Early involvement of the spinal cord in diabetic peripheral neuropathy', *Diabetes Care*. American Diabetes Association, 29(12), pp. 2664–2669. doi: 10.2337/dc06-0650.
- Shekharappa, K. R. *et al.* (2011) 'A Study on the Utility of Nerve Conduction Studies in Type 2 Diabetes Mellitus', *Journal of Clinical and Diagnostic Research*. Bangalore, 5(3), pp. 529–531. Available at: www.jcdr.net (Accessed: 18 March 2021).
- Soriano Caminero, A., Govindarajan, R. and Salgado, E. (2012) 'Is HbA1c Level a Marker for Severity of Diabetic Distal Symmetric Polyneuropathy? (P03.198)', *Neurology*, 78(1 Supplement). Available at: https://n.neurology.org/content/78/1_Supplement/P03.198.short (Accessed: 30 March 2021).
- Tamer, A. *et al.* (2006) 'The Prevalence of Neuropathy and Relationship with Risk Factors in Diabetic Patients: A Single-Center Experience', *Medical Principles and Practice*, 15(3), pp. 190–194. doi: 10.1159/000092180.
- Tesfaye, S. *et al.* (1996) 'Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study', *Diabetologia*. Springer Verlag, 39(11), pp. 1377–1384. doi: 10.1007/s001250050586.
- Tesfaye, S. *et al.* (2005) 'Vascular Risk Factors and Diabetic Neuropathy', *New England Journal of Medicine*. Massachusetts Medical Society, 352(4), pp. 341–350. doi: 10.1056/nejmoa032782.
- Unger, T. *et al.* (2020) '2020 International Society of Hypertension Global Hypertension Practice Guidelines', *Hypertension*. Lippincott Williams and Wilkins, 75(6), pp. 1334–1357. doi: 10.1161/HYPERTENSIONAHA.120.15026.
- Wada, R. and Yagihashi, S. (2005) 'Role of advanced glycation end products and their receptors in development of diabetic neuropathy', in *Annals of the New York Academy of Sciences*. New York Academy of Sciences, pp. 598–604. doi: 10.1196/annals.1338.067.
- Wang, C. *et al.* (2015) 'Evaluating peripheral nerve function in asymptomatic patients with type 2 diabetes or latent autoimmune diabetes of adults (LADA): Results from

- nerve conduction studies', *Journal of Diabetes and its Complications*. Elsevier Inc., 29(2), pp. 265–269. doi: 10.1016/j.jdiacomp.2014.11.001.
- Wang, Y. *et al.* (2006) 'Enhanced inflammatory response via activation of NF- κ B in acute experimental diabetic neuropathy subjected to ischemia-reperfusion injury', *Journal of the Neurological Sciences*. Elsevier, 247(1), pp. 47–52. doi: 10.1016/j.jns.2006.03.011.
- WebMD (2020) *WebMD Diabetes Center*. Available at: <https://www.webmd.com/diabetes/default.htm> (Accessed: 12 March 2020).
- Weisman, A. *et al.* (2013) 'Identification and Prediction of Diabetic Sensorimotor Polyneuropathy Using Individual and Simple Combinations of Nerve Conduction Study Parameters', *PLoS ONE*. Edited by R. Kirchmair. Public Library of Science, 8(3), p. e58783. doi: 10.1371/journal.pone.0058783.
- Weng, Y.-C. *et al.* (2020) 'Diabetic Distal Symmetrical Polyneuropathy: Correlation of Clinical, Laboratory, and Electrophysiologic Studies in Patients with Type 2 Diabetes Mellitus', *Journal of Diabetes Research*. doi: 10.1155/2020/6356459.
- Won, J. C. *et al.* (2012) 'Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with Type 2 diabetes in Korea', *Diabetic Medicine*. John Wiley & Sons, Ltd, 29(9), pp. e290–e296. doi: 10.1111/j.1464-5491.2012.03697.x.
- World Health Organization (2016) *WHO Indonesia Diabetes Country Profile*. Available at: https://www.who.int/diabetes/country-profiles/idn_en.pdf?ua=1 (Accessed: 12 March 2020).
- World Health Organization (2018) *Diabetes, World Health Organization*. Available at: <https://www.who.int/news-room/fact-sheets/detail/diabetes> (Accessed: 12 March 2020).
- Xia, P., Kramer, R. M. and King, G. L. (1995) 'Identification of the mechanism for the inhibition of Na⁺,K⁺-adenosine triphosphatase by hyperglycemia involving activation of protein kinase C and cytosolic phospholipase A₂', *Journal of Clinical Investigation*. The American Society for Clinical Investigation, 96(2), pp. 733–740. doi: 10.1172/JCI118117.
- Yadav, S. B. *et al.* (2014) 'A prospective study of prevalence and association of peripheral neuropathy in Indian patients with newly diagnosed type 2 diabetes mellitus', *Journal of Postgraduate Medicine*. Medknow Publications, 60(3), p. 270. doi: 10.4103/0022-3859.138750.

- Yamagishi, S.-I. *et al.* (2007) ‘Correction of protein kinase C activity and macrophage migration in peripheral nerve by pioglitazone, peroxisome proliferator activated- γ -ligand, in insulin-deficient diabetic rats’, *Journal of Neurochemistry*. John Wiley & Sons, Ltd, 0(0), pp. 071108171001008-??? doi: 10.1111/j.1471-4159.2007.05050.x.
- Yang, C.-P. *et al.* (2015) ‘Cardiovascular Risk Factors Increase the Risks of Diabetic Peripheral Neuropathy in Patients With Type 2 Diabetes Mellitus’, *Medicine*. Lippincott Williams and Wilkins, 94(42), p. e1783. doi: 10.1097/MD.0000000000001783.
- Yang, J. *et al.* (2017) ‘Association between Hemoglobin Levels and Diabetic Peripheral Neuropathy in Patients with Type 2 Diabetes: A Cross-Sectional Study Using Electronic Health Records’, *Journal of Diabetes Research*. Hindawi Limited, 2017. doi: 10.1155/2017/2835981.
- Young, M. J. *et al.* (1993) ‘A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population’, *Diabetologia*. Springer-Verlag, 36(2), pp. 150–154. doi: 10.1007/BF00400697.